Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that

  • 0 views
  • 06 Jun, 2022
  • 1 location
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

A mucosal melanoma postoperative adjuvant treatment of multicenter, randomized, double-blind, placebo-controlled phase II study, evaluation of mucosal melanoma patients accept completely

  • 0 views
  • 24 Mar, 2022
  • 1 location
  • 6 views
  • 24 Jan, 2021
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.

  • 0 views
  • 14 Mar, 2022
  • 1 location
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

microenvironment and benefit patients with mucosal melanoma.

nivolumab
measurable disease
brain metastases
gilbert's syndrome
immunologic adjuvant
  • 0 views
  • 16 Jun, 2022
  • 1 location
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

The main objective will be to estimate the disease free survival (DFS) of patients with resectable head and neck mucosal melanomas treated by neo-adjuvant anti-PD1 followed by surgery

  • 0 views
  • 02 Aug, 2021
  • 1 location
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6)

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy

malignant melanoma of skin
cytotoxic t-lymphocyte antigen 4
metastatic melanoma
BRAF
targeted therapy
  • 0 views
  • 18 May, 2022
  • 9 locations
Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

®) as neoadjuvant therapy for localized mucosal melanoma. Primary objective: To evaluate pathological response (pCR+pPR) rate of Toripalimab combined with axitinib as neoadjuvant therapy for

  • 4 views
  • 22 Mar, 2022
  • 1 location
Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM

Sinonasal mucosal melanoma (SNMM) is a very rare tumor, and SNMM is highly aggressive in nature, with a 5-year survival rate of about 20~30%. Most patients underwent local recurrence and distant

  • 0 views
  • 22 Aug, 2021
  • 1 location
Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

with advanced mucosal melanoma. The target population is the patients with previously untreated, histopathologically confirmed, unresectable or metastatic mucosal melanoma. At the randomization

  • 1 views
  • 06 Feb, 2022
  • 1 location